HONG KONG, Jan. 20, 2026 /PRNewswire/ -- AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on January 19 that it has developed an optimized upgraded version of its iterative ...
Findings showed Capvaxive was noninferior to PPSV23 for each of the 12 serotypes present between the 2 vaccines. Topline data were announced from a phase 3 trial evaluating Merck’s 21-valent ...
In adults living with HIV, the 21-valent pneumococcal conjugate vaccine (PCV) V116 was well tolerated and effective against all 21 target serotypes. The immune responses were comparable to those ...
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory ...
Utilizing pneumococcal conjugate vaccines (PCVs) could save almost 700,000 children's lives between the time of their introduction to the year 2030, according to a new modeling study. This would be ...
What Is It, and Why Does It Matter? Capvaxive is a 21-valent pneumococcal conjugate vaccine (PCV21). It trains your immune system to recognize 21 types of Streptococcus pneumoniae, a germ that can ...
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-8, a Phase 3 trial evaluating CAPVAXIVE™ (Pneumococcal ...
New research published in Blood Advances reveals that since the introduction of pneumococcal conjugate vaccines, PCV7 and PCV13, invasive pneumococcal infection (IPD) rates among children living with ...
A major cause of illness and death worldwide, invasive pneumococcal disease (IPD) is especially burdensome among infants, the elderly, and the immunocompromised. Pneumococcal conjugate vaccines have ...
Data show that commercially and Medicaid-insured children with chronic or immunocompromising conditions incur 2- to 3-fold higher costs. A retrospective cohort study using the Merative MarketScan ...
National-level CDC surveillance data shows CAPVAXIVE covers the serotypes responsible for approximately 84% of invasive pneumococcal disease cases, compared to approximately 52% covered by PCV20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results